241 related articles for article (PubMed ID: 34188585)
1. Efficacy and Safety Profile of Ivosidenib in the Management of Patients with Acute Myeloid Leukemia (AML): An Update on the Emerging Evidence.
Stemer G; Rowe JM; Ofran Y
Blood Lymphat Cancer; 2021; 11():41-54. PubMed ID: 34188585
[TBL] [Abstract][Full Text] [Related]
2. Enasidenib and ivosidenib in AML.
Martelli MP; Martino G; Cardinali V; Falini B; Martinelli G; Cerchione C
Minerva Med; 2020 Oct; 111(5):411-426. PubMed ID: 32955829
[TBL] [Abstract][Full Text] [Related]
3. Ivosidenib to treat adult patients with relapsed or refractory acute myeloid leukemia.
Pasquier F; Lecuit M; Broutin S; Saada S; Jeanson A; Penard-Lacronique V; de Botton S
Drugs Today (Barc); 2020 Jan; 56(1):21-32. PubMed ID: 32055803
[TBL] [Abstract][Full Text] [Related]
4. Preclinical Drug Metabolism, Pharmacokinetic, and Pharmacodynamic Profiles of Ivosidenib, an Inhibitor of Mutant Isocitrate Dehydrogenase 1 for Treatment of Isocitrate Dehydrogenase 1-Mutant Malignancies.
Chen Y; Nagaraja NV; Fan B; Utley L; Lemieux RM; Popovici-Muller J; Dang L; Kim H; Yan L; Su SM; Biller SA; Yang H
Drug Metab Dispos; 2021 Oct; 49(10):870-881. PubMed ID: 34321251
[TBL] [Abstract][Full Text] [Related]
5. Isocitrate dehydrogenase inhibitors in acute myeloid leukemia.
Liu X; Gong Y
Biomark Res; 2019; 7():22. PubMed ID: 31660152
[TBL] [Abstract][Full Text] [Related]
6. Olutasidenib: a novel mutant IDH1 inhibitor for the treatment of relapsed or refractory acute myeloid leukemia.
Cortes JE
Expert Rev Hematol; 2024 Jun; 17(6):211-221. PubMed ID: 38747392
[TBL] [Abstract][Full Text] [Related]
7. The role of mutant IDH1 and IDH2 inhibitors in the treatment of acute myeloid leukemia.
Nassereddine S; Lap CJ; Haroun F; Tabbara I
Ann Hematol; 2017 Dec; 96(12):1983-1991. PubMed ID: 29090344
[TBL] [Abstract][Full Text] [Related]
8. Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness.
Liu ACH; Cathelin S; Yang Y; Dai DL; Ayyathan DM; Hosseini M; Minden MD; Tierens A; Chan SM
Cancer Res; 2022 Dec; 82(23):4325-4339. PubMed ID: 36150062
[TBL] [Abstract][Full Text] [Related]
9. Recent advances of IDH1 mutant inhibitor in cancer therapy.
Tian W; Zhang W; Wang Y; Jin R; Wang Y; Guo H; Tang Y; Yao X
Front Pharmacol; 2022; 13():982424. PubMed ID: 36091829
[TBL] [Abstract][Full Text] [Related]
10. Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML.
DiNardo CD; Stein EM; de Botton S; Roboz GJ; Altman JK; Mims AS; Swords R; Collins RH; Mannis GN; Pollyea DA; Donnellan W; Fathi AT; Pigneux A; Erba HP; Prince GT; Stein AS; Uy GL; Foran JM; Traer E; Stuart RK; Arellano ML; Slack JL; Sekeres MA; Willekens C; Choe S; Wang H; Zhang V; Yen KE; Kapsalis SM; Yang H; Dai D; Fan B; Goldwasser M; Liu H; Agresta S; Wu B; Attar EC; Tallman MS; Stone RM; Kantarjian HM
N Engl J Med; 2018 Jun; 378(25):2386-2398. PubMed ID: 29860938
[TBL] [Abstract][Full Text] [Related]
11. Evaluating ivosidenib for the treatment of relapsed/refractory AML: design, development, and place in therapy.
Nassereddine S; Lap CJ; Tabbara IA
Onco Targets Ther; 2019; 12():303-308. PubMed ID: 30643428
[TBL] [Abstract][Full Text] [Related]
12. The role of enasidenib in the treatment of mutant IDH2 acute myeloid leukemia.
Abou Dalle I; DiNardo CD
Ther Adv Hematol; 2018 Jul; 9(7):163-173. PubMed ID: 30013764
[TBL] [Abstract][Full Text] [Related]
13. Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML.
Choe S; Wang H; DiNardo CD; Stein EM; de Botton S; Roboz GJ; Altman JK; Mims AS; Watts JM; Pollyea DA; Fathi AT; Tallman MS; Kantarjian HM; Stone RM; Quek L; Konteatis Z; Dang L; Nicolay B; Nejad P; Liu G; Zhang V; Liu H; Goldwasser M; Liu W; Marks K; Bowden C; Biller SA; Attar EC; Wu B
Blood Adv; 2020 May; 4(9):1894-1905. PubMed ID: 32380538
[TBL] [Abstract][Full Text] [Related]
14.
Megías-Vericat JE; Ballesta-López O; Barragán E; Montesinos P
Blood Lymphat Cancer; 2019; 9():19-32. PubMed ID: 31413655
[TBL] [Abstract][Full Text] [Related]
15. FDA Approval Summary: Ivosidenib for Relapsed or Refractory Acute Myeloid Leukemia with an Isocitrate Dehydrogenase-1 Mutation.
Norsworthy KJ; Luo L; Hsu V; Gudi R; Dorff SE; Przepiorka D; Deisseroth A; Shen YL; Sheth CM; Charlab R; Williams GM; Goldberg KB; Farrell AT; Pazdur R
Clin Cancer Res; 2019 Jun; 25(11):3205-3209. PubMed ID: 30692099
[TBL] [Abstract][Full Text] [Related]
16. Assessing acquired resistance to IDH1 inhibitor therapy by full-exon
Oltvai ZN; Harley SE; Koes D; Michel S; Warlick ED; Nelson AC; Yohe S; Mroz P
Cold Spring Harb Mol Case Stud; 2021 Apr; 7(2):. PubMed ID: 33832922
[TBL] [Abstract][Full Text] [Related]
17. IDH Inhibitors in AML-Promise and Pitfalls.
McMurry H; Fletcher L; Traer E
Curr Hematol Malig Rep; 2021 Apr; 16(2):207-217. PubMed ID: 33939107
[TBL] [Abstract][Full Text] [Related]
18. Mutant Isocitrate Dehydrogenase Inhibitors as Targeted Cancer Therapeutics.
Golub D; Iyengar N; Dogra S; Wong T; Bready D; Tang K; Modrek AS; Placantonakis DG
Front Oncol; 2019; 9():417. PubMed ID: 31165048
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic/Pharmacodynamic Evaluation of Ivosidenib or Enasidenib Combined With Intensive Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed IDH1/2-Mutant Acute Myeloid Leukemia.
Fan B; Chen Y; Yin F; Hua L; Almon C; Nabhan S; Cooper M; Yang H; Hossain M
Clin Pharmacol Drug Dev; 2022 Apr; 11(4):429-441. PubMed ID: 35166065
[TBL] [Abstract][Full Text] [Related]
20. Ivosidenib: First Global Approval.
Dhillon S
Drugs; 2018 Sep; 78(14):1509-1516. PubMed ID: 30209701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
